Tricuspid valve replacement is a high-risk treatment associated with suboptimal results. Emergent clinical status at surgery, advanced age, pulmonary hypertension, and NYHA class III/IV have been identified as predictive risk factors for operative mortality. The operative mortality ranges from 12 to 26 %. For the tricuspid valve replacement, using a mechanical or biological prostheses valve remains a controversial subject. There are no real differences in mortality, morbidity, and rate of reintervention by type of prosthesis implanted. The range of survival at 5 years is 60-72 %, and at 10 years, it is from 42 to 65 %. Freedom from reoperation is about 85 % at 10 years, comparable in the two groups of prosthesis used.
|Title of host publication||The Tricuspid Valve in Congenital Heart Disease|
|Publisher||Springer-Verlag Italia s.r.l.|
|Number of pages||7|
|ISBN (Print)||9788847054004, 8847053994, 9788847053991|
|Publication status||Published - Feb 1 2014|
ASJC Scopus subject areas